(NASDAQ: XFOR) X4 Pharmaceuticals's forecast annual revenue growth rate of 44.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.43%.
X4 Pharmaceuticals's revenue in 2026 is $33,979,000.On average, 6 Wall Street analysts forecast XFOR's revenue for 2026 to be $943,966,484, with the lowest XFOR revenue forecast at $539,834,112, and the highest XFOR revenue forecast at $1,509,069,798. On average, 5 Wall Street analysts forecast XFOR's revenue for 2027 to be $2,092,359,944, with the lowest XFOR revenue forecast at $556,971,703, and the highest XFOR revenue forecast at $3,711,075,349.
In 2028, XFOR is forecast to generate $10,150,525,110 in revenue, with the lowest revenue forecast at $5,599,445,500 and the highest revenue forecast at $16,598,980,850.